Exelixis, Inc.
EXEL
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressiā¦ read more
Healthcare
Biotechnology
26 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$58.33
Price+1.15%
$0.66
1Y
Price
Market Cap
$14.662b
Large
Price/Earnings 3y Avg5y Avg
16.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+41.8%
EBITDA Margin+33.7%
Net Profit Margin+49.3%
Free Cash Flow Margin+41.8%
EBITDA Margin+33.7%
Net Profit Margin+49.3%
Free Cash Flow MarginRevenue
$2.436b
+5.0%
1y CAGR+10.2%
3y CAGR+11.0%
5y CAGREarnings
$860.623m
+10.0%
1y CAGR+70.3%
3y CAGR+56.2%
5y CAGREPS
$3.19
+14.8%
1y CAGR+81.2%
3y CAGR+64.9%
5y CAGRBook Value
$1.844b
$2.494b
Assets$650.472m
Liabilities$165.929m
DebtDebt to Assets
6.7%
0.2x
Debt to EBITDAFree Cash Flow
$1.181b
+39.9%
1y CAGR+115.0%
3y CAGR+80.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company